Hot times in the intensive care unit by Abraham, Edward
Fever in the context of critical illness is a frequent occur-
rence and can raise the concern that an infection or other 
inﬂ  ammatory process, such as pancreatitis, is present. In 
this situation, the evaluative process for the cause of fever 
may result in important modiﬁ   cations in treatment, 
including initiation or alteration in antimicrobial therapy. 
Fevers can also be a manifestation of drug reactions, 
prompting the discontinuation of suspected agents. 
However, in many cases, fever in a critically ill patient is 
not associated with a treatable etiology and is considered 
simply a symptom that accompanies the organ dysfunc-
tion that brought the patient to the intensive care unit 
(ICU).
Th   e optimal approach to fever in the ICU has not been 
resolved. While reducing fever can improve patient 
comfort, decrease the risk of febrile seizures in the 
predisposed patient, and lower metabolic rate, it remains 
unclear whether antipyretics actually aﬀ  ect patient out-
come in clinically meaningful ways. Never  theless, the use 
of acetaminophen (paracetamol), ibuprofen, and other 
oral agents remains a common practice in both out-
patient and inpatient settings. However, there are limited 
options available for lowering temperature in critically ill 
patients in whom the enteral route cannot be used. 
External cooling measures have only modest eﬀ  ects, 
especially if there is peripheral vasoconstriction, and the 
use of invasive techniques, including chilled intravenous 
ﬂ  uids and peritoneal or extracorporeal cooling measures, 
is generally not indicated for the modest hyperthermia 
commonly present in the ICU.
In the previous issue of Critical Care, a clinical trial 
reported by Morris and colleagues [1] shows that 
intravenous ibuprofen is more eﬀ  ective than placebo in 
lowering temperature to less than 101°C in both critically 
ill and non-critically ill patients. Although there did not 
appear to be an increased incidence of adverse events in 
the patients who received intravenous ibuprofen, this 
study was small, with just 53 critically ill patients, and 
speciﬁ  cally excluded groups of patients commonly seen 
in the ICU, such as those immediately post-surgery, those 
with creatinine of greater than 3  mg/dL, or those 
receiving dialysis or corticosteroid therapy. Th  erefore, 
claims of safety for the use of intravenous ibuprofen in 
critically ill patients need to be well established with 
larger studies before such therapy can be considered for 
routine use.
Concerns about the use of intravenous ibuprofen in the 
ICU are further magniﬁ  ed by the lack of any sugges  tion 
of clinical beneﬁ  t with such therapy. Although a study by 
Bernard and colleagues [2] showed that intra  venous 
ibuprofen was eﬀ   ective in diminishing the severity of 
hyperthermia in patients with acute lung injury, there did 
not appear to be any beneﬁ  cial  eﬀ  ects on survival or 
other meaningful clinical outcomes.
Th  e safety concerns with the use of ibuprofen in 
critically ill patients should not be underestimated. Even 
in healthy patients, ibuprofen and similar nonsteroidal 
anti-inﬂ   ammatory agents are asso  ciated with renal 
dysfunction, particularly in patients with baseline 
evidence of renal compromise [3]. Owing to renal 
hypoperfusion associated with sepsis, hypo  volemia, or 
diminished cardiac output or in response to nephrotoxic 
drugs, such as aminoglycosides, which are frequently 
used in critically ill patients, acute kidney insuﬃ   ciency is 
a common occurrence in the ICU. In the study by Morris 
and colleagues [1], intravenous ibuprofen was adminis-
tered over only a 24-hour period. As fever is often a 
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© 2010 BioMed Central Ltdpersistent problem in critically ill patients, occur  ring 
over many days, the potential use of intravenous 
ibuprofen is unlikely to be limited to only 24 hours. 
Although the present study appears to show that a very 
limited exposure to intravenous ibuprofen in patients 
without evidence of signiﬁ  cant renal dysfunction is not 
associated with signiﬁ  cant harm, we really need to be 
assured of the safety of this intervention over a more 
prolonged period and in more typical ICU populations 
before its routine use can be considered.
Th   e question of whether we should be treating fever at 
all remains. Although there may be some reason to 
believe that massive and prolonged hyperpyrexia is 
harmful, there is little evidence that the more modest 
fevers commonly seen in ICU patients aﬀ  ect their clinical 
outcomes. Until we have such data, there seems to be 
little use in treating fever at all, especially as the 
development of fever may provide an important clue 
alerting us to the need for modifying therapy for patho-
physiologic processes, such as a new infection, that really 
can determine the outcome for a patient.
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